Mayne Pharma Group (CHIA:MYX) - Stock Price, News & Analysis

MYX Stock Overview

MYX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Se prevé un crecimiento anual de los beneficios de 110.2%

Trading a buen valor en comparación con empresas similares e industria

Risk Analysis

No risks detected for MYX from our risk checks.

Mayne Pharma Group Limited Competitors

PharmAust

ASX:PAA

AU$140.0m

Probiotec

ASX:PBP

AU$235.8m

Incannex Healthcare

ASX:IHL

AU$65.1m

Vita Life Sciences

ASX:VLS

AU$129.8m

Price History & Performance

Summary of all time highs, changes and price drops for Mayne Pharma Group
Historical stock prices
Current Share Price	AU$7.16
52 Week High	AU$7.38
52 Week Low	AU$2.71
Beta	1.32
1 Month Change	2.87%
3 Month Change	21.77%
1 Year Change	72.12%
3 Year Change	-17.70%
5 Year Change	-46.57%
Change since IPO	-57.25%

Recent updates

Shareholder Returns

	MYX	AU Pharmaceuticals	AU Market
7D	-1.2%	-1.5%	-1.3%
1Y	72.1%	45.9%	8.7%

Rentabilidad frente al sector: MYX superó al sector Australian Pharmaceuticals , que obtuvo un rendimiento del 67% el año pasado.

Rentabilidad vs. Mercado: MYX superó al mercado Australian, que obtuvo un rendimiento del -0.5% el año pasado.

Price Volatility

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Average Weekly Movement	6.3%
Pharmaceuticals Industry Average Movement	10.9%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: MYXha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MYX (7%) se ha mantenido estable durante el año pasado.

About the Company

Founded	Employees	CEO	Website
2005	n/a	Shawn O’Brien	https://www.maynepharma.com

Mayne Pharma Group Limited, empresa farmacéutica especializada, fabrica y vende productos farmacéuticos de marca y genéricos en Australia, Nueva Zelanda, Estados Unidos, Canadá, Europa, Asia y a escala internacional. La empresa opera a través de cuatro segmentos: Productos de marca internacionales, y División de productos de cartera. Proporciona sistemas de administración oral de fármacos y servicios de desarrollo y fabricación por contrato a clientes externos, además de distribuir productos farmacéuticos especializados en las áreas terapéuticas de dermatología, salud femenina y enfermedades infecciosas.

Mayne Pharma Group Limited Fundamentals Summary

How do Mayne Pharma Group's earnings and revenue compare to its market cap?
MYX fundamental statistics
Market cap	AU$582.64m
Earnings (TTM)	-AU$274.18m
Revenue (TTM)	AU$319.28m

1.8x

P/S Ratio

-2.1x

P/E Ratio

Is MYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MYX income statement (TTM)
Revenue	AU$319.28m
Cost of Revenue	AU$145.07m
Gross Profit	AU$174.21m
Other Expenses	AU$448.39m
Earnings	-AU$274.18m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 23, 2024

Earnings per share (EPS)	-3.38
Gross Margin	54.56%
Net Profit Margin	-85.87%
Debt/Equity Ratio	5.5%

How did MYX perform over the long term?

See historical performance and comparison

MYX Stock Overview

Rewards

Risk Analysis

Mayne Pharma Group Limited Competitors

ASX:PAA

AU$140.0m

ASX:PBP

AU$235.8m

ASX:IHL

AU$65.1m

ASX:VLS

AU$129.8m

Price History & Performance

Recent News & Updates

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Recent updates

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought AU$137k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

Revenue beats expectations

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

New 90-day low: AU$0.32

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day low: AU$0.32

New 90-day low: AU$0.32

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

New 90-day low - AU$0.33

New 90-day low - AU$0.34

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

Shareholder Returns